What are the challenges in blinding participants and therapists in rehabilitation trials?

Clinical trial for ALT | Non-Alcoholic Fatty Liver Disease | Non Insulin Dependent Diabetes , A Prospective, Randomized, Open Label Trial of Two Doses of ... Triheptanoin dramatically reduced by 90% the number of non-epileptic paroxysmal manifestations over 2 months in GLUT1-DS and improved patient's brain energy ... MISSION: A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ... Jan 1, 2025 ... This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population. Jul 31, 2024 ... The main aim is to test how safe and effective the medicine ILUVIEN® (190μg) is for children and adolescents, who have non-infectious ... Open-label studies lack the rigor of blinded studies. Since the lack of blinding can introduce significant bias, reserve the use of open-label studies for ... A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Conclusions: These data suggest that ligands for the gamma subtype of PPARs may represent a novel therapy for ulcerative colitis. A double blind, placebo- ... An Open-label Trial With Plasma Prekallikrein Oligonucleotide Antisense Therapy To Control Angioedema Attacks In Hereditary Angioedema Patients With Normal C1- ... Jan 4, 2024 ... Participants were randomly assigned to treatment with the glucagon-like peptide 1 receptor agonist semaglutide or the sodium–glucose cotransporter 2 inhibitor ...